Advanced

Evaluating combination therapies for asthma: pros, cons and comparative benefits

Bjermer, Leif LU (2008) In Therapeutic Advances in Respiratory Disease 2(3). p.149-161
Abstract
Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes,... (More)
Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Therapeutic Advances in Respiratory Disease
volume
2
issue
3
pages
149 - 161
publisher
SAG
external identifiers
  • pmid:19124367
  • scopus:68749098714
ISSN
1753-4666
DOI
10.1177/1753465808092280
language
English
LU publication?
yes
id
db49d525-50ca-4c2c-8ef5-3197b9b42823 (old id 1275727)
alternative location
http://tar.sagepub.com/content/2/3/149.long
http://www.ncbi.nlm.nih.gov/pubmed/19124367
date added to LUP
2013-08-07 15:46:09
date last changed
2017-03-26 03:46:01
@article{db49d525-50ca-4c2c-8ef5-3197b9b42823,
  abstract     = {Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.},
  author       = {Bjermer, Leif},
  issn         = {1753-4666},
  language     = {eng},
  number       = {3},
  pages        = {149--161},
  publisher    = {SAG},
  series       = {Therapeutic Advances in Respiratory Disease},
  title        = {Evaluating combination therapies for asthma: pros, cons and comparative benefits},
  url          = {http://dx.doi.org/10.1177/1753465808092280},
  volume       = {2},
  year         = {2008},
}